High levels of Fbln2 mRNA expression were indeed significantly associated with improved DMFS in patients with negative LN status (P = 0.03; n = 988), as well as in patients with intermediate grade (Grade II, P = 0.05; n = 546), while there was a statistically insignificant trend towards better survival in low grade breast cancer patients (Grade I, P = 0.14; n = 188). This evidence concerns the gene FBLN2 and breast carcinoma.